18F-Fluorocholine

DUBLIN, Sept. 5, 2022 /PRNewswire/ -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028. Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period. Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging. Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share. Key Market Dynamics Market Drivers Rising Prevalence of Prostate Cancer Surging Demand for Early and Precise Diagnosis of Prostate Cancer Market Restraints High Cost Related to the Prostate Cancer Diagnostics and Treatment Market Opportunities Growing Use of Radiopharmaceuticals in Prostate Cancer Future Trends Increasing Research Activities for Development of Innovative Imaging Agents Company Profiles Blue Earth Diagnostics Limited ImaginAB Curium Jubilant Radiopharma NCM-USA LLC ABX Advanced Biochemical Compounds GmbH Telix Pharmaceuticals Ltd. Novartis AG Theragonostics Lantheus Medical Imaging Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Curium the world’s leading nuclear medicine company, today announced the submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency. The submission comes two months after completing its Phase III PYTHON trial of [18F]-DCFPyL and follows two US pivotal trials – OSPREY and CONDOR by Progenics Pharmaceuticals, Inc., a Lantheus company. In the U.S., [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented: “The positive results of our Phase III PYTHON clinical trial conducted in Europe reinforce the diagnostic performance of [18F]-DCFPyL in the pivotal OSPREY and CONDOR clinical trials in multiple stages of prostate cancer disease, confirming our belief in [18F]-DCFPyL and the role it will play in helping Curium to redefine the experience of cancer.” Benoit Woessmer, PET Europe Chief Executive Officer at Curium added: “With the completion of the PYTHON clinical trial and the submission of our Marketing Authorization Application to the European Medicines Agency, Curium demonstrates its continued dedication and commitment to developing life-saving diagnostic solutions for cancer patients around the world. With our state-of-the-art PET radiopharmacy network – the largest in Europe, Curium will be ready to make the product available across Europe post approval in order to make an everyday impact on patients and people.” PYTHON Study The PYTHON Study (NCT04734184) was a Phase III, European, multicenter, prospective cross-over comparison trial, to evaluate and compare the detection rates, impact on patient management and safety profiles between [18F]-DCFPyL and [18F]-Fluorocholine (the current approved and established gold standard for PET/CT imaging of prostate cancer in Europe), in patients with first biochemical recurrence (BCR) after initial definitive therapy with curative intent. This study successfully met the primary endpoint. The details of the PYTHON study and the clinical results will be presented at the 35th Annual Congress of the European Association of Nuclear Medicine, October 15-19, 2022 in Barcelona, Spain. PYLARIFY® (piflufolastat F 18) Injection In the U.S., [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. U.S. Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level Important Safety Information Contraindications None. Warnings and Precautions Risk of Image Misinterpretation Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Hypersensitivity Reactions Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available. Radiation Risks Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Adverse Reactions The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies with PYLARIFY. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions. Drug interactions Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established. To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For important risk and use information about PYLARIFY Injection, please see Full Prescribing information. About Curium Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com.